This trial is !
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Lupus Nephritis
and you are
between 18 and 70
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the dose-response relationship within the therapeutic range, and select the target dose for phase III development.

Provided treatments

  • Drug: BI 655064 dose 1
  • Drug: BI 655064 dose 2
  • Drug: BI 655064 dose 3
  • Drug: Placebo
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02770170. The sponsor of the trial is Boehringer Ingelheim and it is looking for 120 volunteers for the current phase.
Official trial title:
A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Effect of BI 655064 Administered as Sub-cutaneous Injections, on Renal Response After One Year of Treatment, in Patients With Active Lupus Nephritis